322. Hemophilia A and B: Clinical and Epidemiological: Poster I

Major bleeding and stroke in patients with hemophilia and atrial fibrillation

High treatment compliance and tolerability with fitusiran antithrombin based dose regimen in people with hemophilia A or B with or without inhibitors ATLAS OLE study

Comparative analysis between inhibitor screen and mini bethesda assay to diagnose low titre inhibitors in hemophilia patients an experience from a hemophilia comprehensive care center in India

In vitro comparison of eptacog beta and eptacog alfa with antithrombin lowering simulated fitusiran using thrombin generation assay

HLA alleles associated with inhibitor development in severe hemophilia A Analysis of the My life our Future hemophilia A cohort

A low cost Clinical Prediction model for identifying female hemophilia carriers and women and girls with hemophilia WGH in central China

Cost comparison of prophylactic vs on demand use of a 1 1 ratio pdVWF FVIII concentrate in type 3 von willebrand disease with severe bleeding phenotype in the United States A payer and societal perspective

Concizumab efficacy in patients with Hemophilia A B without inhibitors from the Phase 3 explorer8 study A post hoc sensitivity analysis for the intra patient comparison of concizumab with previous prophylaxis

Real world experience of efanesoctocog alfa in Hemophilia A patients in the US A retrospective analysis

Evolution of joint health and physical activity in people with hemophilia A without factor VIII inhibitors switching to emicizumab prophylaxis A second interim analysis of the BEYOND ABR study